Takeda’s Zasocitinib Shows High Efficacy in Landmark Phase 3 Plaque Psoriasis Trials—Over Half of Patients Achieved Clear or Almost Clear Skin

Phase 3 Results Reveal Zasocitinib’s Strong Efficacy for Moderate-to-Severe Plaque Psoriasis

Takeda (TAK) released topline results from two pivotal Phase 3 clinical trials for zasocitinib (TAK-279), an investigational, highly selective TYK2 inhibitor administered once daily for moderate-to-severe plaque psoriasis. The trials enrolled over 1,800 adults globally and met all primary and ranked secondary endpoints. Notably, more than half of patients receiving zasocitinib achieved PASI 90 (clear or almost clear skin), and around 30% achieved complete skin clearance (PASI 100) at week 16. Efficacy gains continued through week 24, marking zasocitinib as a promising new oral therapy for psoriasis patients seeking effective and convenient treatment options.

Safety Profile Remains Consistent and Well-Tolerated

Zasocitinib maintained a favorable safety profile in these large-scale studies, aligning with results from earlier phases. The most frequently reported adverse events were upper respiratory tract infection, nasopharyngitis, and acne. Importantly, no new safety signals emerged during the trials, providing reassurance about its potential as a daily oral therapy. Takeda confirmed that zasocitinib’s high selectivity for TYK2—more than one million-fold compared to other JAK enzymes—helps maximize effectiveness while limiting risks associated with broader JAK inhibition.

Potential to Transform Treatment for Psoriasis and Beyond

Psoriasis affects approximately 64 million people globally, with plaque psoriasis representing 80-90% of cases. The condition’s burden is not just physical but impacts quality of life and mental health. Current options often require injections or do not achieve complete clearance. Zasocitinib’s once-daily pill, with over half of participants reaching almost clear skin in 16 weeks, could represent a significant shift for patients and physicians alike.

Further, Takeda is extending zasocitinib studies to include comparisons with existing oral competitors and investigating broader indications, including psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Regulatory submission is targeted to start in fiscal year 2026.

What’s Next: Broader Implications and Ongoing Studies

Takeda’s latest data cements zasocitinib’s position as a top contender in oral therapies for immune-mediated diseases. While these Phase 3 results do not alter Takeda’s full-year earnings outlook for 2026, the findings highlight significant promise for future growth if regulatory milestones are met. Takeda will present the full results at upcoming medical congresses and continue head-to-head studies against established treatments.

For patients and investors watching psoriasis innovation, the performance of zasocitinib offers new hope—and raises interesting questions for future competitive dynamics in the oral immunology market.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI